European Journal of Cancer
Volume 37, Issue 3 , Pages 364-368 , February 2001

Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study

  • M. De Lena

      Affiliations

    • Medical-Oncology Department, Oncology Institute of Bari, Via Amendola 209, 70126 Bari, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +390-80-555-5471; fax: +390-80-555-5471
    • ,
  • V. Lorusso

      Affiliations

    • Medical-Oncology Department, Oncology Institute of Bari, Via Amendola 209, 70126 Bari, Italy
    • ,
  • A. Latorre

      Affiliations

    • Medical-Oncology Department, Oncology Institute of Bari, Via Amendola 209, 70126 Bari, Italy
    • ,
  • G. Fanizza

      Affiliations

    • Gynaecological Department, Oncology Institute of Bari, Via Amendolo 209, 70126 Bari, Italy
    • ,
  • G. Gargano

      Affiliations

    • Gynaecological Department, Oncology Institute of Bari, Via Amendolo 209, 70126 Bari, Italy
    • ,
  • L. Caporusso

      Affiliations

    • Medical-Oncology Department, Oncology Institute of Bari, Via Amendola 209, 70126 Bari, Italy
    • ,
  • M. Guida

      Affiliations

    • Medical-Oncology Department, Oncology Institute of Bari, Via Amendola 209, 70126 Bari, Italy
    • ,
  • A. Catino

      Affiliations

    • Medical-Oncology Department, Oncology Institute of Bari, Via Amendola 209, 70126 Bari, Italy
    • ,
  • E. Crucitta

      Affiliations

    • Medical-Oncology Department, Oncology Institute of Bari, Via Amendola 209, 70126 Bari, Italy
    • ,
  • D. Sambiasi

      Affiliations

    • Medical-Oncology Department, Oncology Institute of Bari, Via Amendola 209, 70126 Bari, Italy
    • ,
  • A. Mazzei

      Affiliations

    • Medical-Oncology Department, Oncology Institute of Bari, Via Amendola 209, 70126 Bari, Italy

Received 29 March 2000 ,Revised 1 August 2000 ,Accepted 8 November 2000.

References 

  1. Ozols RF, Schwartz PE, Eifel PJ. Ovarian cancer, fallopian tube carcinoma and peritoneal carcinoma. In De Vita VT, Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology. Philadelphia, JB Lippincott, 1997, 5th edn. 1502–1539.
  2. Neijt JP. New therapy for ovarian cancer. N. Engl. J. Med. 1996;334:50–51
  3. Mc Guire WP, Hoskins WJ, Brady MF, et al.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6
  4. Stuart G, Bertelsen K, Mangioni C, et al. Updated analysis shows a highly significant improved overall survival (OS) for cisplatin-paclitaxel as first line treatment of advanced ovarian cancer: mature results of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottish Intergroup Trial. Proc Am Soc Clin Oncol 1998, 17, 1373 (abstr).
  5. Ozols RF, Bundy BN, Fowler J, et al. Randomized phase III trial study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group Trial (GOG 158). Proc Am Soc Clin Oncol 1999, 18, 1373 (abstr).
  6. duBois A, Lueck HJ, Meier W, et al.  Cisplatin/paclitaxel vs. carboplatin/paclitaxel in ovarian cancer: update of an Arbeitsgemeinschaft Gynaekologische Onkologie (GOG) Study Group Trial. Proc Am Soc Clin Oncol. 1999;18:1374 (abstr)
  7. Neijt JP, Hansen M, Hansen SW, et al.  Randomized phase III study in previously untreated epithelial ovarian cancer FIGO stage IIB, IIC, III, IV, comparing paclitaxel-cisplatin and paclitaxel-carboplatin. Proc Am Soc Clin Oncol. 1997;16:1259 (abstr)
  8. Floridi A, Paggi MG, Marcante ML, Silvestrini B, Caputo A, De Martino C. Lonidamine, a selective inhibitor of aerobic glycolisis of murine tumor cells. J Natl Cancer Inst. 1981;66:497–499
  9. Silvestrini R. Lonidamine: an overview. Semin Oncol. 1991;18:2–6
  10. Silvestrini R, Zaffaroni N, Villa R, Orlandi L, Costa A. Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells. Int. J. Cancer. 1992;52:813–817
  11. Angioli R, Janicek M, Sevin BV, et al.  Use of lonidamine to potentiate the effect of cisplatin and carboplatin on platinum resistant human ovarian cancer cell. Int J Oncol. 1997;11:777–780
  12. De Lena M, De Mitrio A, Catino A, Lorusso V, Brandi M. Recovery after response to platinum with lonidamine in previously treated metastatic ovarian cancer. Preliminary results. Int J Oncol. 1994;4:779–782
  13. De Lena M, Lorusso V, Bottalico C, et al.  Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum. J Clin Oncol. 1997;15:3208–3213
  14. Bottalico C, Lorusso V, Brandi M, et al.  Correlation between HPLC-determined lonidamine serum levelsa and clinical response in patients with advanced ovarian cancer. Anticancer Research. 1996;16:3865–3870
  15. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207–214
  16. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  17. De Cesare M, Pratesi G, Giusti A, Polizzi D, Zunino F. Stimulation of apoptotic response as a basis for the therapeutic synergism of lonidamine and cisplatin in combination in human tumor xenograft. Br J Cancer. 1998;77:434–439
  18. Orlandi L, Zaffaroni N, Bearzatto A, Villa R, De Marco C, Silvestrini R. Lonidamine as a modulator of taxol activity in human ovarian cancer: effects on cell cycle and induction of apoptosis. Int J Cancer. 1998;78:377–384
  19. Ravagnan L, Marzo I, Costantini P, et al.  Lonidamine triggers apoptosis via a direct, Bcl-2 inhibited effect on the mitochondrial permeability transition pore. Oncogene. 1999;18:2537–2546
  20. Biroccio A, Del Bufalo D, Fanciulli M, Bruno T, Zupi G, Floridi A. Bcl-2 inhibits mitochondrial methabolism and lonidamine induces apoptosis in adiamycin-resistant MCF 7 cells. Int. J Cancer. 1999;82:125–130

PII: S0959-8049(00)00400-7

European Journal of Cancer
Volume 37, Issue 3 , Pages 364-368 , February 2001

Article Tools

* Image Usage & Resolution